|
|
 Previous Article | Table of Contents | Next Article 
Immunohistochemical Analysis of Interleukin-1 -Converting Enzyme/Ced-3 Family Protease, CPP32/Yama/Caspase-3, in Hodgkin's Disease
Mukesh Chhanabhai,
Stanislaw Krajewski,
Maryla Krajewska,
Hong-Gang Wang,
John C. Reed, and
Randy D. Gascoyne
From the Department of Pathology, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada and The Burnham Institute, Cancer Research Center, La Jolla, CA.
The Caenorhabditis elegans cell death gene, Ced-3, encodes a protein homologous to mammalian interleukin-1 -converting enzyme (ICE), a cysteine protease implicated in programmed cell death (PCD). CPP32, also known as Yama, apopain, and Caspase-3, is a member of this family, has substrate specificities similar to Ced-3, and has been shown to have an active role in PCD. Evidence suggests that these proteases act downstream of inhibitors of PCD such as Bcl-2 and Bcl-xL , which are frequently expressed in Reed-Sternberg (RS) cells of Hodgkin's disease (HD). To date there have been no studies examining the role of the ICE/Ced-3 family of proteins, in particular CPP32, in HD. We examined 24 cases of HD with a classical immunophenotype and 6 cases of nodular lymphocyte predominant HD (NLPHD) for the expression of CPP32 in the RS cells and lymphohistiocytic (L&H) cells as detected by immunohistochemistry. Twenty two of 24 cases (92%) of HD expressed the protein in the RS cells, whereas the L&H cells in all 6 cases of NLPHD lacked expression of CPP32. These results provide further evidence that NLPHD is a phenotypically different disease distinct from classical forms of HD. The differential expression of the cell death protein CPP32 may be an important factor contributing to the apparently different clinical behaviour of NLPHD in contrast to classical HD. The lack of expression of CPP32 in NLPHD shares similarities with low-grade B-cell non-Hodgkin's lymphomas and may explain their common clinical course. Further studies are required to elucidate the significance of CPP32 in HD.
Blood, Vol. 90 No. 6 (September 15), 1997:
pp. 2451-2455
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Re, R. Kuppers, and V. Diehl
Molecular Pathogenesis of Hodgkin's Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6379 - 6386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Re, R. K. Thomas, K. Behringer, and V. Diehl
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Blood,
June 15, 2005;
105(12):
4553 - 4560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology,
January 1, 2003;
2003(1):
225 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Dukers, C. J. L. M. Meijer, R. L. ten Berge, W. Vos, G. J. Ossenkoppele, and J. J. Oudejans
High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome
Blood,
June 17, 2002;
100(1):
36 - 42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Winter, A. Kramer, A. Borkowski, and N. Kyprianou
Loss of Caspase-1 and Caspase-3 Protein Expression in Human Prostate Cancer
Cancer Res.,
February 1, 2001;
61(3):
1227 - 1232.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. F. Izban, T. Wrone-Smith, E. D. Hsi, B. Schnitzer, M. E. Quevedo, and S. Alkan
Characterization of the Interleukin-1ß-Converting Enzyme/Ced-3-Family Protease, Caspase-3/CPP32, in Hodgkin's Disease : Lack of Caspase-3 Expression in Nodular Lymphocyte Predominance Hodgkin's Disease
Am. J. Pathol.,
May 1, 1999;
154(5):
1439 - 1447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
